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Radiolabeled octreotide analogs are most successfully being
applied today in clinical cancer imaging and treatment. Propagation
of this paradigm to other radiopeptide families has been greatly
hampered by the inherent poor metabolic stability of systemically
administered peptide analogs. We hypothesized that the in vivo
coadministration of specific enzyme inhibitors would improve
peptide bioavailability and hence tumor uptake. Through single
coinjection of the neutral endopeptidase inhibitor phosphoramidon
(PA), we were able to provoke remarkable rises in the percent-
ages of circulating intact somatostatin, gastrin, and bombesin
radiopeptides in mouse models, resulting in a remarkable in-
crease in uptake in tumor xenografts in mice. Methods: The
peptide conjugates [DOTA-Ala1]SS14 (DOTA-Ala-Gly-c[Cys-Lys-
Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys]-OH), PanSB1 (DOTA-
PEG2-DTyr-Gln-Trp-Ala-Val-bAla-His-Phe-Nle-NH2), and DOTA-MG11
(DOTA-DGlu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) were labeled with
111In by 20 min of heating at an acidic pH. Metabolic stability was
studied with high-performance liquid chromatography analysis of
blood samples collected 5 min after the injection of the test radio-
peptide alone or with PA into mice. Biodistribution was studied after
injection of each 111In-labeled radiopeptide alone or after coinjec-
tion of PA in tumor-bearing severe combined immunodeficient
(SCID) mice. Results: The amount of intact [111In-DOTA-Ala1]
SS14 detected in the mouse circulation at 5 min after the injection
of PA increased impressively—from less than 2% to 86%—whereas
the uptake in AR4-2J xenografts rose from less than 1 percentage
injected dose per gram of tissue (%ID/g) to 14%ID/g at 4 h after injection.
Likewise, the coadministration of PA resulted in a marked increase
in the amount of circulating intact 111In-PanSB1—from 12% to 80%—at
5 min after injection, and radioligand uptake in human PC-3 xeno-
grafts in SCID mice escalated from less than 4 %ID/g to greater than
21 %ID/g at 4 h after injection. In a similar manner, the coadminis-
tration of PA resulted in an equally impressive increase in intact [111In-
DOTA]MG11 levels in the mouse bloodstream—from less than 5%
to 70%—at 5 min after injection, leading to a remarkable increase in
radiotracer uptake—from 2 %ID/g to greater than 15 %ID/g—in both
AR4-2J tumors and A431(CCKR1) tumors (i.e., tumors induced by
A431 cells transfected to stably express the human cholecystokinin
subtype 2 receptor) in mice at 4 h after injection. This effect was well
visualized by SPECT/CT imaging of AR4-2J tumor–bearing mice at
4 h after injection. Conclusion: The results of this study clearly
demonstrate that the coadministration of key enzyme inhibitors
can effectively prolong the survival of radiolabeled peptides in the
circulation, securing their safe transit to the target. This strategy
clearly provoked an unprecedented increase in radiolabel accumu-
lation in tumor xenografts in mice; this increase might translate into
higher diagnostic sensitivity or improved therapeutic efficacy of
radiopeptide drugs in cancer patients. Hence, our findings provide
exciting new opportunities for the application of biodegradable (ra-
dio)peptide drugs of either natural or synthetic origin as well as for
the rationale design of analogs that are stable in vivo.
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The overexpression of peptide receptors on the cell membrane
of cancer cells, as opposed to their lower level of expression in
healthy surrounding tissues, has provided the unique opportunity
to visualize and treat malignant tumors in cancer patients with the
aid of radiolabeled peptide analogs, that is, radiopeptides (1–3).
Radiopeptide drugs are carefully designed to carry the radionuclide
of choice specifically to their receptor target located at primary and
metastatic tumor sites. With a diagnostic radionuclide, g photons
detected by an external imaging device, such as a SPECT or PET
camera, enable the highly specific visualization of tumor lesions.
With a therapeutic radionuclide, particle radiation can induce tumor
cell apoptosis and death (4–6). With the advent of [111In-diethyl-
enetriaminepentaacetic acid (DTPA)]octreotide, this approach has
been successfully implemented in clinics for the diagnosis of so-
matostatin receptor–positive neuroendocrine tumors (7). With the
introduction of [177Lu-DOTA0,Tyr3]octreotate, this approach has
been further pursued in phase 3 clinical studies of somatostatin
receptor–targeted therapy of neuroendocrine tumors (8,9). Further-
more, other regulatory peptide receptors amply expressed in alter-
native cancer types have emerged as putative targets of newly de-
veloped radiopeptide ligands (3).
The success of this strategy relies largely on the safe delivery of
the intact radiopeptide to its receptor target after intravenous
injection into the living organism. Radiopeptide integrity and,
hence, target delivery are challenged immediately on entry into
the circulation by ubiquitous proteolytic enzymes present in the
blood or anchored to the surface of blood cells and vasculature
walls. Furthermore, during transit through major organs, such as
the liver, lungs, kidneys, and gastrointestinal tract, radiopeptides
are exposed to more enzymes residing in abundance in these
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compartments. The relationships among native peptide ligands,
their cognate receptors, and endogenous enzymes orchestrating
their close interactions have long been acknowledged both in
normal conditions and in cancer. In the search for peptide analogs
resistant to assailing enzymes, various structural modifications—
such as key amino acid substitutions, reduction or methylation of
biodegradable bonds, cyclization, multimerization, and other
means—have been proposed (10,11). This search is costly and
time-consuming and typically yields analogs with suboptimal
pharmacologic characteristics.
We propose instead the as-yet-unexplored application of
enzyme inhibitors to optimize radiopeptide supply to tumor-
associated receptor targets, with the aim of increasing diagnostic
sensitivity and improving therapeutic efficacy against primary and
disseminated disease. Through the coinjection of a single inhibitor
of neutral endopeptidase (NEP; EC 3.4.24.11; neprilysin; CD10)
(12) in experimental animals, we were able to provoke marked
increases in the percentages of intact circulating radiopeptide ana-
logs of the somatostatin, gastrin, and bombesin peptide families.
Most importantly, we were able, for the first time, to our knowl-
edge, to induce an impressive amplification of radiopeptide uptake
in a variety of tumor xenografts in mice expressing the respective
receptor targets.
Specifically, we intravenously injected phosphoramidon (PA)
together with different radiopeptides in mice. PA is a potent and
reversible competitive NEP inhibitor, and the structure of PA
bound to the active site of human NEP has been elucidated (13).
By virtue of its high level of water solubility, PA can be injected as
a bolus together with a radiopeptide in doses ensuring the effective
in vivo inhibition of NEP. It was first isolated from cultures of
Streptomyces tanashiensis, but methods for its convenient synthe-
sis recently became available (14,15).
Three types of 111In-labeled and DOTA-modified radioligands
representing the somatostatin-14, bombesin, and gastrin peptide
types were included in the present study. As a first example, we
describe the effect of PA coinjection on the stability and localiza-
tion of [111In-DOTA-Ala1]SS14 (111In-DOTA-Ala-Gly-c[Cys-Lys-
Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys]-OH) in somatostatin
subtype 2 receptor (sst2)–expressing AR4-2J tumors in mice (16).
Our second example involves the bombesin analog 111In-PanSB1
([111In-DOTA-PEG2-DTyr-Gln-Trp-Ala-Val-bAla-His-Phe-Nle-
NH2), which is based on a previously reported sequence exhibit-
ing a pan–bombesin receptor binding profile (17–19). The effect
of PA on in vivo stability and tumor uptake was studied and
assessed with human PC-3 xenografts expressing the gastrin-
releasing peptide receptor (GRPR) in mice (20,21). Our third ex-
ample encompasses the gastrin–cholecystokinin peptide family.
The effect of PA coinjection on the in vivo stability of [111In-
DOTA]MG11 (111In-DOTA-DGlu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-
NH2) and on uptake in 2 tumor models in mice—a double A431-
CCK2R(1) and A431-CCK2R(2) xenograft (i.e., induced by
inoculation of A431 cells transfected to stably express the human
cholecystokinin subtype 2 receptor [CCK2R] and of A431 cells
devoid of CCK2R expression, respectively) and the CCK2R-
expressing AR4-2J tumor model—was assessed (22–24). [111In-
DOTA]MG11 was previously reported to have a favorably low level
of renal accumulation; however, compared with full-chain gastrin
analogs, [111In-DOTA]MG11 was associated with a lower level of
metabolic stability and reduced tumor targeting (23,25).
The findings of the present study revealed a prominent role for
NEP in the in vivo processing of N-terminal radiometallated
peptides, consistent with its ubiquitous and abundant presence in
the human body (12). The significance of NEP involvement in the
catabolism of the radiopeptides tested in the present study and pre-
sumably further classes of radiopeptide ligands has not yet been
adequately assessed and warrants further investigation. Therefore,
we believe that the present preliminary study will stimulate further
research to unravel the key role of major peptidases engaged in the
catabolism of intravenously administered (radio)peptide drugs.
MATERIALS AND METHODS
Materials and Instrumentation
Chemicals were reagent grade. The peptides used in this study were
synthesized or purchased from commercial sources. [DOTA-Ala1]SS14,
[Tyr3]octreotate (H-DPhe-c[Cys-Tyr-DTrp-Lys-Thr-Cys]-Thr-OH), and
demogastrin 2 [N4-Gly-DGlu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-
NH2] were synthesized on solid support as previously described
(16,24). PanSB1 and DOTA-MG11 were purchased from PiChem,
and [Tyr4]bombesin (Pyr-Gln-Arg-Tyr-Gly-Asn-Gln-Trp-Ala-Val-
Gly-His-Leu-Met-NH2) was obtained from Bachem AG. PA [N-
(a-rhamnopyranosyloxyhydroxyphosphinyl)-L-leucyl-L-tryptophan ·
2Na · 2H2O] was purchased from PeptaNova GmbH. For 111In labeling,
111InCl3 in 50 mM HCl at an activity concentration of 370 MBq/mL on
the calibration date was purchased from Mallinckrodt Medical BV.
Radiochemical high-performance liquid chromatography (HPLC)
analyses were performed on a Waters chromatograph with a model
600 solvent delivery system, coupled to both a model 996 photodiode-
array UV detector (Waters) and a Gabi g detector (Raytest RSM
Analytische Instrumente GmbH); the Millennium Software (Waters)
was used to control the HPLC system and process the data. Radioac-
tivity in samples was measured in an automatic well-type g counter
(NaI(Tl) 399-crystal; Canberra Packard Auto-Gamma 5000 series in-
strument). SPECT/CT images were acquired with a 4-head multipin-
hole NanoSPECT/CT camera (Bioscan Inc.) at the Animal Imaging
Facility at Erasmus MC.
111In Labeling and Quality Control
Labeling with 111In was conducted by adding 10 nmol of peptide
analog per 37–74 MBq of 111InCl3 in 0.1 M sodium acetate buffer and
10 mM sodium ascorbate. The typical end pH was 4.6. Labeling was
complete after incubation in a boiling water bath for 20 min (26).
Before HPLC quality control procedures, ethylenediaminetetraacetic
acid in 0.1 M acetate buffer was added at a final concentration of 1
mM to the labeling reaction mixture as a free 111In31 scavenger (27).
For DOTA-MG11, Met (5 mL of a 0.1 M solution) was added to the
labeling reaction mixture to prevent oxidation of the Met residue to
the corresponding sulfoxide (28).
For radiochemical analyses, an XBridge Shield RP18 column (5 mm;
4.6 · 150 mm; Waters) coupled to the respective 2-cm guard column was
used. Elution was accomplished with a linear gradient of a 0.1% tri-
fluoroacetic acid–water solution and acetonitrile (starting at 10% aceto-
nitrile, with a 1% increase per minute) at a flow rate of 1 mL/min.
Cell Cultures
Rat pancreatic tumor cell line AR4-2J endogenously expressing the
sst2 and rat gastrin/CCK2R was kindly provided by Stephen Mather
(St. Bartholomew’s Hospital, London, U.K.) and cultured as previously
described (29,30). Human androgen–independent prostate adenocarci-
noma PC-3 cells (LGC Promochem) endogenously expressing the hu-
man GRPR (20) were cultured in Dulbecco modified Eagle medium
with GlutaMAX-I (Gibco BRL Life Technologies) and supplemented
with 10% (v/v) heat-inactivated fetal bovine serum, penicillin at
100 U/mL, and streptomycin at 100 mg/mL. Human epidermoid car-
cinoma cell line A431 transfected to stably express the human CCK2R
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[A431-CCK2R(1)] or devoid of CCK2R expression [A431-CCK2R
(2)] was a kind gift from Otto C. Boerman (Department of Nuclear
Medicine, Radboud University Nijmegen Medical Centre, Nijmegen,
The Netherlands) and Luigi Aloj (Istituto di Biostrutture e Bioimma-
gini, Consiglio Nazionale delle Ricerche, Naples, Italy). Transfected
cells were cultured in Dulbecco modified Eagle medium with Gluta-
MAX-I and supplemented as described earlier but with G418 (Genet-
icin; Gibco BRL Life Technologies; 250 mg/mL) added to the medium
(22). All culture reagents were obtained from Gibco BRL Life Tech-
nologies or from BiochromKG Seromed. Cells were kept in a controlled
humidified atmosphere containing 5% CO2 at 37C. Cells were
inspected for confluence, and 1:3 or 1:4 passages were performed (usu-
ally every 2–5 d, according to cell type) with a 0.05% trypsin–0.02%
ethylenediaminetetraacetic acid (w/v) solution.
Metabolic Studies in Mice
A bolus of a test 111In-labeled radiopeptide solution (100 mL; 11–22
MBq; 3 nmol of total peptide in physiologic saline–ethanol [9:1, v/v]),
together with vehicle (100 mL of physiologic saline–ethanol [9:1, v/v])
(control group) or PA (100 mL of vehicle containing 300 mg of PA)
(PA-treated group), was injected into the tail veins of healthy Swiss
albino mice (National Center for Scientific Research “Demokritos”
Animal House). At 5 min after injection, blood (0.5–1 mL) was col-
lected from the hearts of the animals and immediately transferred to
prechilled polypropylene tubes containing ethylenediaminetetraacetic
acid, and the tubes were placed on ice. For [111In-DOTA]MG11, the
tubes also contained Met (final concentration of 1 mM) to prevent
oxidation of the Met residues to the respective sulfoxides. Blood
samples were centrifuged (10 min, 2,000g, 4C; Hettich Universal
320R centrifuge), the plasma was collected and mixed with chilled
acetonitrile in a 1:1 (v/v) ratio, and the samples were centrifuged again
(10 min, 15,000g, 4C). Supernatants were concentrated to a small
volume under a gentle N2 flux at 40C, diluted with physiologic saline
(400 mL), and filtered through a Millex GV filter (0.22 mm).
Aliquots were analyzed by reversed-phase HPLC with a Symmetry
Shield RP18 column (5 mm; 3.9 · 20 mm; Waters). Elution was
accomplished in 50 min at a flow rate of 1 mL/min with the following
gradient: 100% A and 0% B to 50% A and 50% B, where Awas 0.1%
trifluoroacetic acid in H2O and B was acetonitrile. The elution times
of intact radiotracers were determined by coinjection of the respective
111In-labeled radiopeptide.
Biodistribution of 111In-Labeled Radioligands in Xenograft-
Bearing severe combined immunodeficient (SCID) Mice
SCID mice that were 6 wk old on the day of arrival (National Center
for Scientific Research “Demokritos” Animal House) were inoculated
in their flanks with a bolus (150 mL) containing a suspension of 1 ·
107–2 · 107 freshly harvested cells in sterile physiologic saline. The animals
were kept under aseptic conditions until palpable tumors developed at the
inoculation site. Palpable tumor development took 12 d, 3 wk, and 6 d for
AR4-2J (3506 20 mg [mean6 SD]), PC-3 (1506 30 mg), and A431-
CCKR(1) or A431-CCKR(2) tumors (260 6 80 mg), respectively.
On the day of the experiment, a bolus of a test 111In-labeled radio-
peptide solution (100 mL; 37–74 kBq; 10 pmol of total peptide in vehicle),
together with vehicle (100 mL) (control group), or PA (100 mL of vehicle
containing 300 mg of PA) (PA-treated group), or PA plus a receptor
blocker (100 mL of vehicle containing 300 mg of PA and excess receptor
blocker) (in vivo receptor blockade group), was injected into the tail veins
of mice. For [111In-DOTA]MG11, Met at a final concentration of 1 mM
was also included. For in vivo receptor blockade, animals were coinjected
with PA and 40 nmol of [Tyr3]octreotate (sst2 blockade), 40 nmol of [Tyr4]
bombesin (GRPR blockade), or 40 nmol of demogastrin 2 (CCK2R
blockade). Animals for each group were se-
lected at random. Furthermore, 2 additional
groups of AR4-2J tumor–bearing animals were
injected with [111In-DTPA]octreotide together
with either vehicle (100 mL) (control group)
or PA (100 mL of vehicle containing 300 mg
of PA) (PA-treated group).
Animals were euthanized in groups of 4 at
4 h after injection. Samples of blood and
urine as well as organs of interest were col-
lected and weighed, and radioactivity was
measured in an automatic well-type g counter.
Data were calculated as the percentage in-
jected dose per gram of tissue (%ID/g) with
the aid of standard solutions and Microsoft
Excel. Results are reported as the mean 6
SD, as calculated with the PRISM 2.01
(GraphPad) software program.
Statistical analysis with the unpaired
2-tailed Student t test was performed to com-
pare values for control, PA-treated, and in
vivo receptor blockade animal groups at 4 h
after injection. P values of less than 0.05
were considered statistically significant.
SPECT/CT Imaging of
[111In-DOTA]MG11 in AR4-2J
Tumor–Bearing Nude Mice
NMRI nu/nu mice (body weight, 30 g;
Harlan CPB) were inoculated subcutaneously
in the shoulder region with 106 AR4-2J cells
(injection volume, 200 mL). When the tumors
reached a diameter of approximately 1 cm, the
FIGURE 1. (A and B) HPLC analysis of blood collected 5 min after injection of [111In-DOTA-Ala1]
SS14 into healthy mice without (A) or with (B) coinjection of PA. (C) Tissue distribution data at 4 h
after injection of [111In-DOTA-Ala1]SS14 without PA, with PA, or with PA plus excess sst2 blocker
coinjection into male SCID mice bearing AR4-2J xenografts; values for tumors are shown in inset.
Ad5 adrenal glands; Bl5 blood; Fe 5 femur; He 5 heart; In5 intestines; Ki5 kidneys; Li 5 liver;
Lu 5 lungs; Mu 5 muscle; Pa 5 pancreas; Sp 5 spleen; St 5 stomach; Tu 5 AR4-2J tumors.
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animals were scanned. During imaging, the animals were anesthetized
with isoflurane (Nicholas Pyramal Ltd.). Body temperature was con-
trolled with a heated bed. After completion of the examinations, the
animals were euthanized.
All animals received [111In-DOTA]MG11 (45 MBq; 0.5 nmol), to-
gether with vehicle or PA (300 mg), through the tail veins at 4 h before
SPECT imaging (total injection volume, 200 mL). SPECT/CT images
were acquired with a 4-head multipinhole SPECT/CT camera with
energy peak settings at 171 and 245 keV (window width 6 10%) for
111In. Nine-pinhole apertures (diameter, 1.4 mm) were used on each
camera head (detector, 230 · 215 mm). The matrix was 256 · 256. The
animals were placed in the center of rotation; the radius of rotation was
fixed. SPECT images were acquired with 20 projections, 60 s per pro-
jection, and a quality factor of 0.8. The images were reconstructed
by use of the ordered-subset expectation maximization method with
HiSPECT NG software (Scivis Wissenschaftliche Bildverarbeitung
GmbH), 24 iterations, and a voxel size of 0.3 · 0.3 · 0.3 mm. CT images
were acquired with the following settings: 180 projections, 45-kVp
tube voltage, 500-ms exposure time, and a voxel size of 0.2 · 0.2 ·
0.2 mm. The images were reconstructed by use of the exact-cone-beam
filtered backprojection algorithm. SPECT images were resampled to
the CT resolution and registered to CT images by use of the VivoQuant
program (version 1.22; inviCRO LLC).
All animal experiments were performed in compliance with
European and national regulations and after approval of protocols
by national authorities.
RESULTS
111In-Labeled Radiotracers
The incorporation of 111In into the DOTA chelator coupled to
the 3 peptide analogs was accomplished by heating at 90C for
20 min in an acidic medium, in agreement with the results of
a previous study (26). As demonstrated by reversed-phase HPLC
of the labeling reaction mixtures, all three 111In-labeled radiotracers
were eluted as a single radiochemical species (.95% purity).
Effect of PA on In Vivo Stability and AR4-2J Tumor Uptake of
[111In-DOTA-Ala1]SS14 in Mice
The effect of PA coinjection on the stability and tumor
localization of [111In-DOTA-Ala1]SS14 in mouse models is shown
in Figure 1. Analysis of blood samples collected 5 min after
[111In-DOTA-Ala1]SS14 injection into healthy mice revealed al-
most total degradation of the radiopeptide (,2% remaining intact
analog) (Fig. 1A) (16,31). After the coinjection of PA, however,
the amount of parent radiopeptide still present in the blood rose to
86% (Fig. 1B). Most importantly, this increase in the levels of
circulating intact radiotracer translated into an impressive ampli-
fication of radiolabel levels in AR4-2J tumors at 4 h after injection
into SCID mice. In particular, the uptake in sst2-expressing tumors
rose from less than 1 %ID/g to 14 %ID/g (Fig. 1C and inset),
whereas tumor uptake declined to less than 0.3 %ID/g after the
coinjection of both PA and excess [Tyr3]octreotate; these results
implied an sst2-mediated process. In contrast, at 4 h after the in-
jection of metabolically stable [111In-DTPA]octreotide, the uptake
in AR4-2J tumors (n 5 7) was 5.5 6 1.0 %ID/g in the control
group and 5.6 6 1.0 %ID/g in the PA-treated group.
Effect of PA on In Vivo Stability and Human PC-3 Xenograft
Uptake of 111In-PanSB1 in Mice
Figure 2A shows the fast breakdown of 111In-PanSB1, within
5 min after entry into the bloodstream of healthy mice. Remark-
ably, the coadministration of PA resulted in an impressive increase
in the levels of circulating 111In-PanSB1,
from 12% to 80% (Fig. 2B). Consistent
with this observation, the uptake of radio-
activity in human GRPR–positive PC-3
xenografts in SCID mice escalated from
less than 4 %ID/g to greater than 21 %ID/g
at 4 h after coinjection of the radiopeptide
with PA (Fig. 2C and inset). The uptake in
human xenografts was reduced to less than
0.9 %ID/g by the coinjection of both PA
and excess [Tyr4]bombesin, demonstrating
GRPR specificity.
Effect of PA on In Vivo Stability and
A431-CCK2R(1) Tumor Uptake of
[111In-DOTA]MG11 in Mice
HPLC analysis of blood samples col-
lected 5 min after injection of [111In-
DOTA]MG11 revealed only 5% intact
radiopeptide in mouse blood (Fig. 3A).
Treatment with PA led to a notable in-
crease in the levels of circulating [111In-
DOTA]MG11 to 70% (Fig. 3B). The im-
pact of this increase on the tumor uptake of
[111In-DOTA]MG11 was studied in a dou-
ble-tumor model in SCID mice (23). The
coinjection of PA induced a striking in-
crease in uptake, from 2 %ID/g to greater
than 15 %ID/g, but only in A431-CCK2R
(1) tumors and not in A431-CCK2R(2)
tumors (Fig. 3C and inset). CCK2R-negative
FIGURE 2. (A and B) HPLC analysis of blood collected 5 min after injection of 111In-PanSB1 into
healthy mice without (A) or with (B) coinjection of PA. (C) Tissue distribution data at 4 h after
injection of 111In-PanSB1 without PA, with PA, or with PA plus excess GRPR blocker coinjection
into female SCID mice bearing human PC-3 xenografts; values for tumors are shown in inset. Bl5
blood; Fe 5 femur; He5 heart; In 5 intestines; Ki5 kidneys; Li5 liver; Lu5 lungs; Mu 5muscle;
Pa 5 pancreas; Sp 5 spleen; St 5 stomach; Tu 5 PC-3 tumors.
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tumors had poor uptake (,0.5 %ID/g) independent of the coin-
jection of PA. An interesting feature of this experiment was the
finding that renal radiopeptide uptake remained low and unaf-
fected by treatment with PA.
Effect of PA on AR4-2J Tumor Uptake of [111In-DOTA]MG11
in Mice: Visualization with SPECT/CT
Treatment with PA resulted in a profound increase in [111In-
DOTA]MG11 uptake in AR4-2J tumors (endogenously expressing
the rat CCK2R), from less than 2 %ID/g to greater than 16 %ID/g,
at 4 h after injection. After the coinjection of PA and excess
demogastrin 2 (24), tumor uptake declined to 0.3 %ID/g, indicat-
ing CCK2R-mediated accumulation (Fig. 4A and inset). These
findings were reproduced by the excellent tumor visualization
on images acquired by SPECT/CT small-animal imaging of
AR4-2J tumor–bearing mice, certifying the positive impact of this
approach on tumor visualization (Figs. 4B and 4C).
DISCUSSION
The last 2 decades have witnessed spectacular progress in
experimental and clinical oncology. Recent advances include the
documentation of peptide receptor expression on the surface of
cancer cells at a density exceeding that in healthy surrounding
tissues. Peptide receptors belong to the superfamily of serpentine G
protein–coupled receptors (GPCRs), and their role in cancer is be-
coming increasingly recognized (1–3). Nuclear medicine research-
ers have taken advantage of recent advances and have implemented
new molecular tools based on radiolabeled peptide ligands to local-
ize and combat primary and metastatic disease. Radiopeptides have
been suitably designed to carry radionuclides of choice, attractive
either for SPECT (g emitters) or PET (positron emitters) imaging or
for radionuclide therapy (a, b, or Auger electron emitters) to lesion-
associated GPCR targets with a high specificity (4,6).
Of particular relevance is the current successful clinical
application of radiolabeled somatostatin analogs in the diagnosis,
staging, and therapy of neuroendocrine tumors overexpressing the
sst2. The success of this strategy has been largely dependent on the
high level of metabolic stability of the radiopeptides used. In
contrast to the rapidly biodegradable native somatostatin-14
(31), sst2-directed radiopeptide drugs (e.g., [111In-DTPA]octreo-
tide) are based on cyclic octapeptide analogs, such as octreotide,
that are robust in vivo (7–9). The prevalence of neuroendocrine
tumors is rather low, and other putative GPCR targets for radio-
peptide ligands are abundantly expressed in frequently occurring
human cancers (3). For example, GRPRs are highly expressed in
human prostate, breast, and lung cancers and have been proposed
as targets for bombesin-like radioligands (32,33). The impact of
radiopeptides on clinical oncology could be tremendously in-
creased if the success of [111In-DTPA]octreotide could be trans-
lated to another radiopeptide family.
However, success in this respect remains limited, partly because
of the poor metabolic stability of radiopeptide drugs. To overcome
this problem, several structural modifications have been pursued,
but metabolic stability typically improves only at the cost of
receptor affinity or the pharmacokinetic profile after radiopeptide
injection into a living organism (10,11). On the other hand, assays
widely used to assess radiopeptide meta-
bolic stability usually involve in vitro in-
cubation in mouse or human serum. As
a result, the action of enzymes anchored
to vasculature walls or blood cells or resid-
ing in major organs (lungs, kidneys, liver,
and intestines) exposed to circulating drugs
is totally disregarded, and metabolic stabil-
ity is erroneously overestimated (34).
In the present study, we explored an
exciting new approach to enhancing tu-
mor targeting; in this approach, an en-
zyme inhibitor and a radiopeptide are
intravenously coadministered in vivo.
The inhibitor–radiopeptide pair are advan-
tageously selected so that the radiopeptide
is protected by the inhibitor immediately
on entry into the circulation and until it
reaches its tumor-associated receptor tar-
get. Therefore, only transient inhibition
has been pursued and has been found ad-
equate to safeguard the transit of the
radiopeptide to the target. It is reasonable
to assume that the increased tumor uptake
induced by this strategy will eventually
translate into higher diagnostic sensitivity
and improved therapeutic efficacy of
radiopeptide drugs in cancer patients.
We demonstrated the feasibility of this
approach with a series of radiopeptides
based on the somatostatin, bombesin, and
gastrin peptide families. Through the coin-
jection of a single NEP inhibitor, PA
FIGURE 3. (A and B) HPLC analysis of blood collected 5 min after injection of [111In-DOTA]
MG11 into healthy mice without (A) or with (B) coinjection of PA. (C) Tissue distribution data at 4 h
after injection of [111In-DOTA]MG11 without PA or with PA coinjection into male SCID mice
bearing A431-CCK2R(1) and A431-CCK2R(2) xenografts; values for tumors are shown in inset.
Bl5 blood; Fe5 femur; He5 heart; In5 intestines; Ki5 kidneys; Li5 liver; Lu5 lungs; Mu5muscle;
Pa 5 pancreas; Sp 5 spleen; St 5 stomach; Tu 2 5 A431-CCK2R(2) tumors; Tu 1 5 A431-
CCK2R(1) tumors.
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(12,13), and a test radiopeptide, we were able, for the first time, to
our knowledge, to induce a marked increase in tumor uptake in
mouse models and to relate this result to a notable improvement in
the level of the circulating intact drug. Of great significance is the
fact that PA had no measurable effect on the tumor uptake of
metabolically stable [111In-DTPA]octreotide in the same animal
sst2-positive model used for [111In-DOTA-Ala1]SS14. This finding
strongly supports our basic assumption that the observed increase
in tumor uptake was a direct result of enhanced radiopeptide bio-
availability induced through NEP inhibition by PA. The profound
impact of the administration of a single NEP inhibitor on the
bioavailability and in vivo tumor targeting of the radiopeptides
tested in the present study is indeed astonishing in view of the
large number of proteases present in the human body. The human
degradome features at least 569 proteases and their homologs,
comprising the 5 classes of metalloproteinases, serine proteases,
cysteine proteases, threonine proteases, and aspartic proteases.
Even more proteases are represented in the mouse and rat degra-
domes, which encompass 644 and 629 members, respectively
(35,36). Therefore, although NEP seems to play a key role in
initiating the breakdown of the radiopeptides tested in the present
study and perhaps other radiopeptides, we
continue our studies to reveal other poten-
tial candidates.
The proposed strategy may have signif-
icant consequences for biodegradable
radiopeptides, even those based on native
sequences (16,31). The latter have been
evolutionarily optimized for best interact-
ing with their cognate receptors. It is
expected that this approach will rapidly
broaden the application of more radiopep-
tide analogs to an increasing number of
cancer classes. In addition, this approach
provides a versatile means for identifying
enzymes actually responsible for the in
vivo degradation of a particular radiopep-
tide drug. This information may be essen-
tial for the rationale design of new, sta-
bilized radiopeptide analogs but may also
have consequences for other peptide drugs,
such as peptide-conjugated cytotoxic drugs,
optical imaging peptide probes, or peptidic
ligands selected by phage display technol-
ogies (37).
CONCLUSION
The results of the present study empha-
size the significance of radiopeptide in
vivo stability as a key element of success-
ful tumor targeting for cancer visualization
and therapy in living subjects. Unexpect-
edly, our findings indicate that the action
of a single peptidase (i.e., NEP) is re-
sponsible for the rapid in vivo breakdown
of intravenously administered radiopepti-
des from at least the somatostatin, bomb-
esin, and gastrin peptide families.
Most importantly, our findings provide
the exciting opportunities to “protect” bio-
degradable radiopeptides and to “serve” in enhancing their supply
and accumulation at tumor sites through the mere coinjection of
a protease inhibitor, such as PA. Such amplification of radiolabel
levels on tumor lesions is expected to strongly boost diagnostic
sensitivity and therapeutic efficacy. In addition, there is a rich
reservoir of information about existing peptidase inhibitors,
a few of which have successfully been tested in human studies
or are even approved drugs, highlighting the potential of this
strategy for translation into clinical practice.
The proposed novel concept of radiopeptide drug–enzyme inhib-
itor coinjection to optimize tumor uptake is particularly valid for
molecular imaging and therapy procedures. Because nuclear med-
icine protocols involve single or a limited number of systemic drug
administrations, they require short-term enzyme inhibition only.
Protection is essentially needed for the period between intravenous
radiopharmaceutical injection and delivery to the tumor-associated
receptor target—a period that is rather brief for small and rapidly
localizing radiopeptide ligands. For such purposes, water-soluble
agents “escorting” the radiopeptide over the hydrophilic body com-
partments and inducing fast and transient enzyme inhibition repre-
sent an elegant route for optimizing tumor targeting.
FIGURE 4. (A) Biodistribution of [111In-DOTA]MG11 at 4 h after injection without PA, with PA, or
with PA plus excess CCK2R blocker coinjection into AR4-2J tumor–bearing mice; values for
tumors are shown in inset. Bl 5 blood; Fe 5 femur; He 5 heart; In 5 intestines; Ki 5 kidneys;
Li 5 liver; Lu 5 lungs; Mu 5 muscle; Pa 5 pancreas; Sp 5 spleen; St 5 stomach; Tu 5 AR4-2J
tumors. (B and C) SPECT/CT at 4 h after injection of [111In-DOTA]MG11 without (B) or with (C)
coinjection of PA (n 5 3 per group). Note the highly improved tumor visualization in C.
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